Ryan Wilcox is an Oncology physician. ClinicalTrials.gov lists 9 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1500 E Medical Center Dr
Ann Arbor, MI 481095000
Telephone
734-936-4000Provider last certified this registry record 5 Nov 2020.
Clinical trials
- Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
Sponsor: University of Michigan Rogel Cancer Center
- Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
Sponsor: University of Michigan Rogel Cancer Center
- Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Sponsor: SciTech Development, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- KYOWA KIRIN, INC.Program year20251 payment
- Incyte CorporationProgram year20221 payment
- Kyowa Kirin, Inc.Program year20223 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
8 NIH research awards on record, funded 2013–2026 per NIH RePORTER. The latest:
- Novel Multi-targeted Strategies Targeting T-cell Lymphomas and their Microenvironment
University of Michigan at Ann Arbor
FY2026$646,920R01CA306891 - Notch ligands as oncogenic drivers and therapeutic targets in T-cell lymphomas
University of Michigan at Ann Arbor
FY2026$602,869R01CA278976 - Novel therapeutic strategies targeting the enhancer landscape in high-risk T-cell lymphomas.
University of Michigan at Ann Arbor
FY2026$401,115R21CA316106
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”